Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.45 |
| ▸ | GPR119 | Q8TDV5 | 6/20 | 0.42 |
| ▸ | KDM1A | O60341 | 2/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23578772 | 1.00 | HRH3 (0.45) | HRH3GPR119KDM1ACNR1CNR2 | |
| SCHEMBL29407322 | 1.00 | HRH3 (0.45) | HRH3GPR119KDM1ACNR1CNR2 | |
| SCHEMBL30078344 | 0.91 | GPR119 (0.42) | HRH3GPR119KDM1ANAMPTCYP11B2 | |
| SCHEMBL29855712 | 0.91 | GPR119 (0.40) | HRH3GPR119KDM1ACYP11B2 | |
| SCHEMBL26648280 | 0.91 | GPR119 (0.40) | HRH3GPR119KDM1ACYP11B2 | |
| SCHEMBL23579295 | 0.89 | GPR119 (0.43) | HRH3GPR119KDM1ANAMPTCYP11B2 | |
| SCHEMBL28946663 | 0.89 | GPR119 (0.43) | HRH3GPR119KDM1ANAMPTCYP11B2 | |
| SCHEMBL29748489 | 0.88 | GPR119 (0.41) | GPR119KDM1ANAMPT | |
| SCHEMBL27222865 | 0.88 | GPR119 (0.41) | GPR119KDM1ANAMPT | |
| SCHEMBL28946628 | 0.88 | GPR119 (0.42) | HRH3GPR119KDM1ANAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12552784-B2 | 1H-pyrrolo[2,3-b]pyridine derivatives as BCL-2 inhibitors for the treatment of neoplastic and autoimmune diseases | NEWAVE PHARMACEUTICAL INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-20230119463-A1 | 1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC AND AUTOIMMUNE DISEASES | NEWAVE PHARMACEUTICAL INC. | 2023-04-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230119463-A1 | 1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC AND AUTOIMMUNE DISEASES | BCL2, BAK1, BCL2A1 | HRH3 3551/4885GPR119 3862/4885KDM1A 1177/4885 |
| US-12552784-B2 | 1H-pyrrolo[2,3-b]pyridine derivatives as BCL-2 inhibitors for the treatment of neoplastic and autoimmune diseases | BCL3, BCL2A1, BCL6 | HRH3 2114/4885GPR119 1607/4885KDM1A 3532/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.